Judo Bio, a biotechnology company pioneering oligonucleotide medicines delivered to the kidney, today announced that the company will present mechanistic and preclinical data that demonstrate the use ...

Research by Stony Brook Medicine nephrology specialists may help prevent or reduce diabetic kidney disease progression by ...

New research by Stony Brook Medicine nephrology specialists that centers on targeting key cellular signaling between two ...

Cambridge, USA-based biotech Judo Bio has announced the company’s launch and $100 million in initial financing, including ...

Newly launched Judo Bio aims to develop ligand-siRNA conjugates through its Selectively Targeting RNA Into KidnEy (STRIKE) ...

Adequate potassium intake is crucial for maintaining various bodily functions, but changes in potassium levels may not pose ...